A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.

Andrew J. Armstrong,Susan Halabi,Patrick Healy,William R. Lee,Bridget F. Koontz,Judd W. Moul,Kelly Mundy,Patricia Creel,Sarah Yenser Wood,Kristen Davis,M. A. Carducci,Mark N. Stein,Carey Hobbs,B Reimer,M Nguyen,Monika Anand,L. Bratt,Sung Kim,Phuoc T. Tran,Daniel J. George

A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.

2016

A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy

Keywords:

Prostate-specific antigen
Benign prostatic hyperplasia (BPH)
Urology
Prostatectomy
Prostate cancer
Radiation therapy
Sunitinib
Oncology
Internal medicine
Salvage therapy
Medicine
Docetaxel
Prednisone

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations